Selected immunohistochemical prognostic factors in endometrial cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 576-582

  Markova, Ivana ^a,b   Duskova, Milada ^b,c   Lubusky, Marek ^b,c   Kudela, Milan ^b,c   Zapletalová, Jana ^a   Procházka, Martin ^b,c   Pilka, Radovan ^b,c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Department of Pathology ^*  (Czech Republic)

Author keywords

Endometrial cancer; Immunohistochemistry; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; KI 67 ANTIGEN; MATRILYSIN; MATRIX METALLOPROTEINASE 26; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIUM CANCER; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952268076     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181d80ac4     Document Type: Article

References (54)

1. ÚZIS (Ústav zdravotnických informacý a statistiky ĈR ve spolupráci s Národným onkologickým registrem ĈR). Novotvary 2005 ĈR.
2. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640-649.
3. Ascher SM, Reinhold C. Imaging of cancer of the endometrium. Radiol Clin North Am. 2002;40:563-576.
4. Canavan TP, Doshi NR. Endometrial cancer. Am Fam Physician. 1999;59:3069-3077.
5. American Cancer Society. Detailed guide: endometrial cancer. Available at: http://documents.cancer.org/140.00/140.00pdf. Accessed September 9, 2008.
6. Goodman MT, Hankin JH, Wilkens LR, et al. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res. 1997;57:5077-5085.
7. Creasman WT. Malignant tumors of the uterine corpus. In Rock JA, Jones HW, eds. Operative Gynecology. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1445-1486.
8. Kodama S, Kase H, Tanaka K, et al. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet. 1996;53:23-30.
9. Geisler JP, Wiemann MC, Zhou Z, et al. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol. 1996;61:245-248.
10. Cherchi PL, Marras V, Capobianco G, et al. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur J Gynaecol Oncol. 2001;22:451-453.
11. Lax SF, Pizer ES, Ronnett BM, et al. Clear cell carcinoma of the endometrium is characterized by adistinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol. 1998;29:551-558.
12. Ohkouchi T, Sakuragi N, Watari H, et al. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol. 2002;187:353-359.
13. Erdem O, Erdem M, Dursum A, et al. Angiogenesis, p53 and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathological variables. Int J Gynecol Pathol. 2003;22:254-260.
14. Sakuragi N, Ohkouchi T, Hareyama H, et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer. 1998;79:153-158.
15. Yamauchi N, Sakamoto A, Uozaki H, et al. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol. 1996;15:202-208.
16. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer. 1994;73:2380-2385.
17. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev. 2003;27:434-441.
18. Ferrandina G, Ranelletti FO, Gallotta V, et al. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER) and progesterone (PR), p53, Ki-67, and neu protein in endometrial cancer. Gynecol Oncol. 2005;98:383-389.
19. Salvesen HB, Iversen OE, Akslen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res. 1998;4:2779-2785.
20. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999;17:1382-1390.
21. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol. 2001;22:122-126. (Pubitemid 32963063)
22. Kadar N, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol. 1993;50:281-286.
23. Morris PC, Anderson JR, Anderson B, et al. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol. 1995;56:406-411.
24. Ueno H, Yamashita K, Azumano I, et al. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer. 1999;84:470-477.
25. Pilka R, Norata GD, Domanski H, et al. Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol. 2004;94:661-670.
26. Brown DC, Gatter KC. Monoclonal antibody Ki67: its use in histopathology. Histopathology. 1990;17:489-503.
27. Rolitsky CD, Theil KS, Mc Gaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Am J Pathol. 1999;18:138-143.
28. Apolinario RM, van der Valk P, de Jong JS, et al Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected nonYsmall-cell lung cancer. J Clin Oncol. 1997;15:2456-2466.
29. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
30. Jalava P, Kuopio T, Huovinen R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res. 2005;25:2535-2542.
31. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical for estrogen receptor and progesterone receptor status cancer: analysis for a cut-off point as the predictor for therapy. Breast Cancer. 2004;11:267-275.
32. Soong R, Knowles S, Williams KE, et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer. 1996;74:562-567.
33. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol. 1997;150:177-185.
34. Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol. 1996;61:167-174.
35. Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer. 2001;11:339-348.
36. Geisler JP, Geisler HE, Wiemann MC, et al. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrium carcinoma. Gynecol Oncol. 1998;71:305-307.
37. Appel M L M, Edelweis MI, Fleck J, et al. p53 and bcl-2 as prognostic markers in endometrial carcinoma. Pathol Oncol Res. 2008;14:23-30.
38. Geisler JP, Geisler HE, Miller GA, et al. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol. 1999;75:432-436.
39. Nordstrom B, Strang P, Bergstrom R, et al. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer. 1996;78:1942-1951.
40. Pansare V, Munkarah AR, Schimp V, et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol. 2007;20:35-43.
41. Ioffe OB, Papadimitriou JC, Drachenberg CB, et al. Correlation of proliferation indices, apoptosis and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic and malignant endometrium. Hum Pathol. 1998;29:1150-1159.
42. Khalifa MA, Mannel RS, Haraway SD, et al. Expression of EGRF, HER-2/neu, p53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53:84-92.
43. Mattias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569-577.
44. Williams JA Jr, Wang ZR, Parrish RS, et al. Fluorescence in situ hybridisation analysis of HER-2/neu, c-myc and p53 in endometrial cancer. Exp Mol Pathol. 1999;67:135-143.
45. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24:2376-2385.
46. Coronado PJ, Vidart JA, Lopez-asenjo JA, et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol. 2001;98:103-108.
47. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol. 1995;14:98-106.
48. Jazaeri AA, Nunes KJ, Dalton MS, et al. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001;20:6965-6969.
49. Nyholm HC, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol. 1995;59:347-351.
50. Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 1998;69:220-225.
51. Graesslin O, Cortez A, Uzan C, et al. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer. 2006;16:1911-1917.
52. Wang FQ, So J, Reierstad S, et al. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005;114:19-31.
53. Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial cancer. Cancer. 2003;97:79-89.
54. Tunuguntla R, Ripley D, Sang QX, et al. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer small star, filled. Gynecol Oncol. 2003;89:453-459.